Madrigal defied the typical 12-18 month pre-launch hiring window by bringing in a new CEO just seven months before approval. He leveraged his network to quickly assemble an experienced commercial team he had worked with before, enabling the company to build a sales force and launch in record time.

The commercial success curve of a new drug is locked in within the first six to nine months post-launch. After this point, market perceptions are set, and additional investment yields diminishing returns. A rapid, real-time feedback loop is crucial for course-correction *during* this make-or-break period.

Rather than waiting for late-stage development, biotech startups should integrate commercial planning into early trials. This means building in data collection for payers, pricing, and patient access from the start. This "think with the end in mind" approach ensures the company has the right data for pivotal trials and market access.

The CEO frames commercial readiness not as a future state post-approval, but as a current identity. This mindset emphasizes that building the team, strategy, and infrastructure for a launch is a multi-year process that defines the company's present operations, not just its future ambitions.

When Ionis announced its strategic shift from a partnership model to a wholly-owned pipeline, investors were skeptical due to the company's 30-year history. Despite liking the new vision, they waited for tangible proof, only rewarding the stock after Ionis successfully launched its first independent products.

In Biotech, risk is removed pre-FDA approval via clinical trials, making a Chief Development Officer (clinical, regulatory, manufacturing) the most critical hire. In many MedTech sectors, risk is removed post-FDA approval via market adoption, making a Chief Commercial Officer paramount.

The increasing volume of new therapies requires pharma companies to stop treating each launch as a unique event. Instead, they must develop a scalable, repeatable, and excellent launch capability to handle the future pipeline efficiently and consistently.

When launching new products, large companies should avoid a big-bang rollout. Instead, use a phased approach: start with 5 reps to find product-market fit, expand to 50 to build a scalable go-to-market playbook, and only then deploy to the full 500-person sales force for mass scaling.

A sophisticated capital strategy involves mapping out major industry milestones, like a competitor's Phase 3 data release. By timing your company's human proof-of-concept (POC) data to land just before that event, you can capitalize on peak market attention and position your asset favorably.